News

Search:
 Search

Latest News | 11 June 2012

FDA Extends Review of Gilead Sciences' Controversial HIV PrEP Drug Truvada

0 Likes

The US Food and Drug Administration (FDA) will take an additional three months to review Gilead Science’s pre-exposure prophylaxis (PrEP) drug Truvada (tenofovir/emtricitabine) to assess Read More...


RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

New Regulatory Focus Apps for iPad and iPhone